Skip to main content

Table 1 Baseline characteristics by study and treatment group in women from the EPAT and WELL-HART trials

From: Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study

Characteristic EPAT (n = 127)   WELL-HART (n = 105)   
  Placebo (n = 57) ET (n = 70) P Placebo (n = 37) ET (n = 34) EPT (n = 34) P* P
Age at baseline mammogram, years (mean ± SEM) 62.3 ± 1.0 60.2 ± 0.8 0.10 64.7 ± 1.0 61.8 ± 1.2 64.1 ± 1.1 0.15 0.005
Years since menopause at baseline (mean ± SEM) 15.1 ± 1.4 12.5 ± 1.0 0.12 18.6 ± 1.6 15.9 ± 1.4 19.5 ± 1.9 0.28 0.001
Number of deliveries (live and stillbirths) (mean ± SEM) 2.4 ± 0.2 2.3 ± 0.2 0.75 4.5 ± 0.6 3.6 ± 0.4 4.1 ± 0.5 0.47 0.0001
Race, n (%)         
White, non-latina 34 (59.7) 40 (57.1)   12 (32.4) 7 (20.6) 14 (41.2)   
Black, non-latina 6 (10.5) 10 (14.3)   4 (10.8) 10 (29.4) 5 (14.7)   
Latina 10 (17.5) 13 (18.6)   20 (54.1) 9 (26.5) 11 (32.4)   
Asian or Pacific Islander 7 (12.3) 7 (10.0) 0.91 1 (2.7) 8 (23.5) 4 (11.8) 0.01 0.0005
Education, n (%)         
High school graduate or less 8 (14.0) 9 (12.9)   20 (54.1) 15 (44.1) 15 (44.1)   
Trade or business school/some college 29 (50.9) 33 (48.6)   11 (29.7) 12 (35.3) 13 (38.2)   
Bachelor's degree or more 20 (35.1) 27 (38.6) 0.92 6 (16.2) 7 (20.6) 6 (17.7) 0.90 0.0001
Family history of breast cancer (first-degree relative), n (%) 9 (15.8) 6 (8.6) 0.21 2 (5.4) 7 (20.6) 3 (8.8) 0.14 0.91
Age at menarche, years (mean ± SEM) 12.7 ± 0.2 12.6 ± 0.2 0.86 12.7 ± 0.3 12.8 ± 0.3 13.3 ± 0.3 0.32 0.21
Ever used postmenopausal hormones, n (%) 36 (63.2) 42 (60.0) 0.72 13 (35.1) 15 (44.1) 21 (61.8) 0.08 0.02
BMI, kg/m2 (mean ± SEM) 28.7 ± 0.7 28.7 ± 0.7 0.96 30.8 ± 1.0 31.4 ± 1.0 30.2 ± 1.1 0.73 0.007
Mammographic density at baseline, % (mean ± SEM) 17.8 ± 2.3 22.3 ± 1.9 0.13 7.9 ± 1.8 10.8 ± 2.1 13.3 ± 2.3 0.19 0.0001
  1. *Comparison of characteristics by treatment group, χ2 test for comparison of categorical variables, analysis of variance for comparison of means; comparison of characteristics between trials (EPAT versus WELL-HART), χ2 test for comparison of categorical variables, analysis of variance for comparison of means; Fisher's exact test. EPAT, Estrogen in the Prevention of Atherosclerosis Trial; ET, 1 mg/day micronized 17β-estradiol; EPT, 1 mg/day micronized 17β-estradiol with 5 mg/day medroxyprogesterone acetate for days 19 to 30 each month; WELL-HART, Women's Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial.